Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

You Lu

Showing results (531-540 of 547) with videos related to

Pageof 55
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2023
Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non-Small Cell Lung Cancer PatientsXiaojuan Zhou, Laiyan Zhou, Zhuoran Yao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 12, 2020
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)Yunpeng Yang, Zhehai Wang, Jian Fang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2020
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 TrialJames Chih-Hsin Yang, D Ross Camidge, Cheng-Ta Yang, et al.
Nature Cancer|June 15, 2023
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLCCaicun Zhou, Ziping Wang, Meili Sun, et al.
Journal of Cancer Research and Clinical Oncology|June 14, 2023
Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS studyQing Zhou, He-Long Zhang, Li-Yan Jiang, et al.
Journal of the National Cancer Institute|January 30, 2022
Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung CancerXiao-Shan Wang, Yi-Feng Bai, Vivek Verma, et al.
Nature Medicine|April 29, 2020
Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancerYou Lu, Jianxin Xue, Tao Deng, et al.
Nature Medicine|June 20, 2020
Publisher Correction: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancerYou Lu, Jianxin Xue, Tao Deng, et al.
The Lancet. Oncology|June 16, 2025
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trialCaicun Zhou, Ziping Wang, Meili Sun, et al.
Med (New York, N.Y.)|July 4, 2024
Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancerHui Wang, Zhuoran Yao, Kai Kang, et al.
Pageof 55

Showing results (531-540 of 547) with videos related to

Sort By:
Pageof 55
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2023
Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non-Small Cell Lung Cancer PatientsXiaojuan Zhou, Laiyan Zhou, Zhuoran Yao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 12, 2020
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)Yunpeng Yang, Zhehai Wang, Jian Fang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2020
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 TrialJames Chih-Hsin Yang, D Ross Camidge, Cheng-Ta Yang, et al.
Nature Cancer|June 15, 2023
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLCCaicun Zhou, Ziping Wang, Meili Sun, et al.
Journal of Cancer Research and Clinical Oncology|June 14, 2023
Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS studyQing Zhou, He-Long Zhang, Li-Yan Jiang, et al.
Journal of the National Cancer Institute|January 30, 2022
Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung CancerXiao-Shan Wang, Yi-Feng Bai, Vivek Verma, et al.
Nature Medicine|April 29, 2020
Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancerYou Lu, Jianxin Xue, Tao Deng, et al.
Nature Medicine|June 20, 2020
Publisher Correction: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancerYou Lu, Jianxin Xue, Tao Deng, et al.
The Lancet. Oncology|June 16, 2025
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trialCaicun Zhou, Ziping Wang, Meili Sun, et al.
Med (New York, N.Y.)|July 4, 2024
Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancerHui Wang, Zhuoran Yao, Kai Kang, et al.
Pageof 55